Filing Flows

Filing Flows › Companies › Ironwood Pharmaceuticals › Cash flow

Ironwood Pharmaceuticals cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow$67.4M in Q3 2026 · $205M over twelve months

Operating cash flow$67.4M
Free cash flow+$67.4M
Cash / net income1.1×

Analysis

In Q3 2026, Ironwood Pharmaceuticals generated $67.4M of operating cash flow. That is $19.8M more than in Q3 2025 ($47.6M).

Over the twelve months to Sep 30, 2026, operating cash flow was $205M; the largest uses were other financing ($260M); besides operations, cash came from shares issued ($425K); the cash balance fell by $54.0M.

Operating cash flow was $67.4M against net income of $59.8M — 1.1× profit, cash ran ahead of reported earnings. The largest differences: deferred taxes +$20.1M, receivables −$20.0M, stock-based pay +$4.3M.

Free cash flow

Ironwood Pharmaceuticals: free cash flow by quarterIronwood Pharmaceuticals: free cash flow by quarter$15.2MQ4 2024$19.9MQ1 2025−$15.1MQ2 2025$47.6MQ3 2025$74.6MQ4 2025$5.1MQ1 2026$58.3MQ2 2026$67.4MQ3 2026
Operating cash flow less capital spending.
Ironwood Pharmaceuticals: operating cash flow against capital spendingIronwood Pharmaceuticals: operating cash flow against capital spendingOperating cash flowCapital spending$15.2M$0Q4 2024$20.0M$31KQ1 2025−$15.1M$2KQ2 2025$47.6M$2KQ3 2025$74.6M−$1KQ4 2025$5.1M$0Q1 2026$58.3M$0Q2 2026$67.4M$0Q3 2026
Latest (Q3 2026): Operating cash flow $67.4M, Capital spending $0.

Capital allocation, year by year

Ironwood Pharmaceuticals: where the cash came from (up) and went (down), by fiscal yearIronwood Pharmaceuticals: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingBuybacksFY2021: Operating cash flow $262MFY2021: Shares issued $19.6MFY2021: Capital spending −$265KFY2021: Buybacks −$24.1M$281MFY2021FY2022: Operating cash flow $274MFY2022: Net borrowing −$121MFY2022: Shares issued $9.5MFY2022: Capital spending −$136KFY2022: Buybacks −$126M$283MFY2022FY2023: Operating cash flow $183MFY2023: Net borrowing $300MFY2023: Shares issued $6.4MFY2023: Capital spending −$273K$490MFY2023FY2024: Operating cash flow $104MFY2024: Net borrowing −$115MFY2024: Shares issued $11.0MFY2024: Capital spending −$142K$115MFY2024FY2025: Operating cash flow $127MFY2025: Shares issued $216KFY2025: Capital spending −$34K$127MFY2025
Over these 5 years operating cash flow totalled $950M; the largest uses were net borrowing ($236M) and buybacks ($151M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$86.4M
Debt$200M
Net debt$113M

Ironwood Pharmaceuticals funds itself: free cash flow was $205M over the last twelve months, and $86.4M of cash and investments stands against $200M of debt.

Where the cash came from and went

Ironwood Pharmaceuticals: sources (+) and uses (−) of cash, Q3 2026Ironwood Pharmaceuticals: sources (+) and uses (−) of cash, Q3 2026Operating cash flow$67.4MOther financing−$60.0MCash drawn (+) / kept (−)−$7.2MExchange rates−$152K
Ironwood Pharmaceuticals: sources (+) and uses (−) of cash, TTM to Q3 2026Ironwood Pharmaceuticals: sources (+) and uses (−) of cash, TTM to Q3 2026Other financing−$260MOperating cash flow$205MCash drawn (+) / kept (−)$54.0MShares issued$425KExchange rates$170KNot reconciled$1K

From profit to cash

Ironwood Pharmaceuticals: net income to operating cash flow, Q3 2026Ironwood Pharmaceuticals: net income to operating cash flow, Q3 2026Net income$59.8MDepreciation & amortization$459KStock-based pay$4.3MDeferred taxes$20.1MReceivables−$20.0MPayables$1.3MPrepaid and other assets$387KOther liabilities−$204KOperating cash flow$67.4M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026$67.4M———−$7.2M$67.4M
Q2 2026$58.3M———$141M$58.3M
Q1 2026$5.1M———−$5.0M$5.1M
Q4 2025$74.6M$1K—$122K−$75.0M$74.6M
Q3 2025$47.6M−$2K——−$47.6M$47.6M
Q2 2025−$15.1M−$2K—$88K$15.6M−$15.1M
Q1 2025$20.0M−$31K—$6K−$19.9M$19.9M
Q4 2024$15.2M—−$15.0M$203K−$348K$15.2M

Ironwood Pharmaceuticals: income statement and cash flow

Ironwood Pharmaceuticals, Q3 2026: revenue $133M (+9% year over year), operating margin 70.0%. The chart follows the revenue to costs, profit and cash.

Ironwood Pharmaceuticals: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.